Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 199,886 shares of the medical technology company's stock after acquiring an additional 33,362 shares during the quarter. Russell Investments Group Ltd. owned about 0.14% of Alphatec worth $1,835,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ATEC. R Squared Ltd acquired a new position in shares of Alphatec during the fourth quarter valued at about $29,000. Nisa Investment Advisors LLC increased its holdings in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after buying an additional 4,234 shares during the period. Newton One Investments LLC acquired a new position in Alphatec in the 4th quarter worth approximately $50,000. XTX Topco Ltd acquired a new position in Alphatec in the 3rd quarter worth approximately $69,000. Finally, AlphaQuest LLC acquired a new position in Alphatec in the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Piper Sandler increased their price target on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Needham & Company LLC restated a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. Finally, Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Alphatec has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 50,000 shares of the firm's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the sale, the chief executive officer now directly owns 6,152,544 shares of the company's stock, valued at $74,015,104.32. This trade represents a 0.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Scott Lish sold 27,453 shares of the business's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 272,113 shares of company stock valued at $3,121,225 in the last three months. 22.80% of the stock is currently owned by insiders.

Alphatec Price Performance

ATEC stock traded up $0.10 during midday trading on Thursday, reaching $11.31. The stock had a trading volume of 235,095 shares, compared to its average volume of 2,041,678. The company's fifty day simple moving average is $10.38 and its 200 day simple moving average is $9.57. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -8.83 and a beta of 1.20. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.